Sanofi to acquire Synthorx to bolster its immuno-oncology pipeline for $2.5 Billion

• Proprietary immuno-oncology (IO) platform synergistic with Sanofi’s existing therapeutic platforms  
• Lead asset THOR-707 (“not-alpha” IL-2) being explored across multiple solid tumor types alone and in combination with immune checkpoint inhibitors and other future IO combinations
• Pre-clinical pipeline for oncology and autoimmune disorders

 

PARIS and San Diego, California – December 9, 2019 – Sanofi and Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology company focused on prolonging and improving the lives of people suffering from cancer and autoimmune disorders, entered into a definitive agreement under which Sanofi will acquire all of the outstanding shares of Synthorx for $68 per share in cash, which represents an aggregate equity value of approximately $2.5 billion (on a fully diluted basis). The transaction was unanimously approved by both the Sanofi and Synthorx Boards of Directors.

 
Read the full press release here.